Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

Aminolevulinic Acid 113-ingenyl angelate 9Photochemotherapy 5Imiquimod 5Fluorouracil 4Petrolatum 3Solutions 2SR-T100 2Gels 2Cryotherapy 2potassium dobesilate 1perillyl alcohol 1endonuclease V, phage T4 1dehydroftorafur 1calcipotriene 1afamelanotide 1Triamcinolone 1Therapies, Investigational 1Papillomavirus Vaccines 1Ointments 1Melatonin 1Lasers 1LEO 43204 1Isotretinoin 1Imipramine 1Excipients 1Eflornithine 1Deoxyribonuclease (Pyrimidine Dimer) 1Cholecalciferol 1Chemexfoliation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Keratosis, Actinic × LEO 43204 × Clear all
NCT02305888 2025-03-10

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

LEO Pharma

Phase 2 Completed
189 enrolled 9 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡